Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Top Page
Xeris Pharmaceuticals
(NASDAQ:XERS)
Select Model
Select Model
Rating:56Neutral
Price Target:
$6.00
▼(-0.33% Downside)
Action:ReiteratedDate:03/03/26
The score is driven mainly by improved financial performance in 2025 (profitability inflection and positive free cash flow) and a constructive earnings outlook with strong 2026 growth guidance. These positives are tempered by weak technicals (downtrend/negative momentum), balance-sheet leverage risk, and limited valuation support given the negative P/E and no dividend yield.
Positive Factors
Strong multi-year revenue growth
Xeris delivered durable top‑line expansion (44% FY2025) driven by product adoption and commercial execution. Persistent multi-year revenue growth builds scale, funds reinvestment, and underpins margin and cash‑flow improvement, supporting longer‑term self‑funding of R&D and commercialization.
High and improving gross margins
Very high gross margins reflect specialty product mix and favorable pricing dynamics. Sustained 80%+ gross margins provide structural earnings leverage, enabling the company to scale operating investments (sales, R&D) while preserving cash generation potential and supporting durable profitability.
Profitability inflection and positive cash flow
2025 marked a structural inflection: first full‑year net income, positive adjusted EBITDA and positive operating/free cash flow. Consistent cash generation reduces reliance on external financing, strengthens funding capacity for Phase III and commercialization, and materially improves long‑term financial flexibility.
Negative Factors
Elevated leverage and fragile equity history
Although debt fell in 2025, remaining leverage and recent history of negative equity leave limited balance‑sheet resilience. This structural fragility increases vulnerability to adverse clinical, competitive, or commercial setbacks and could constrain strategic optionality or force costly financing under stress.
Product concentration risk (Recorlev)
Most incremental revenue is concentrated in Recorlev, making overall results highly sensitive to that single product's commercial and regulatory trajectory. Concentration raises persistent execution risk: uptake, competitive dynamics, or payor actions on one product could materially swing company performance.
ANDA filings and patent litigation uncertainty
Pending ANDA filings and ensuing litigation create structural uncertainty around Recorlev exclusivity and timing of generic entry. Legal outcomes could materially affect long‑term revenue projections for the company’s main growth driver and prolong overhang on strategic planning and market access.
Xeris Pharmaceuticals (XERS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05B
Dividend YieldN/A
Average Volume (3M)1.79M
Price to Earnings (P/E)2273.2
Beta (1Y)1.35
Revenue Growth42.05%
EPS Growth76.50%
CountryUS
Employees394
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.06
Shares Outstanding172,431,290
10 Day Avg. Volume2,907,852
30 Day Avg. Volume1,789,793
Financial Highlights & Ratios
PEG Ratio-22.52
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue3.21
Enterprise Value/Gross Profit3.92
Enterprise Value/Ebitda26.71
Forecast
1Y Price Target
$9.67Price Target Upside60.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.18
Revenue Forecast (FY)$368.00M
Xeris Pharmaceuticals Business Overview & Revenue Model
Company DescriptionXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
How the Company Makes MoneyXeris Pharmaceuticals generates revenue primarily through the commercialization of its proprietary products, such as XeriJect and other formulations in its pipeline. The company's revenue model includes sales of these products to healthcare providers and patients, as well as potential licensing agreements with larger pharmaceutical companies. Additionally, Xeris may benefit from partnerships that provide upfront payments, milestone payments, and royalties based on sales of partnered products. The company’s focus on innovative delivery systems positions it to capture market share in the growing injectable drug market, thereby contributing to its overall earnings.
Xeris Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 02, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive tone driven by robust revenue growth (44% FY), first full-year net income, strong adjusted EBITDA ($59.4M), high gross margins (85%+), a strengthened balance sheet and ambitious 2026 guidance (>30% growth midpoint). Management is investing meaningfully in commercial expansion and a high-value pipeline asset (XP-8121) with planned R&D and SG&A step-ups to support future growth. Primary risks highlighted include newly filed Recorlev patent litigation with uncertain timelines, concentration of growth in Recorlev, and near-term increases in R&D and SG&A expenditures that will be absorbed to enable longer-term upside.Q4-2025 Updates
Positive Updates
Strong Top-Line Growth
Total revenue for FY2025 was $291.8M, an increase of 44% year-over-year; Q4 revenue was $85.8M, up 43% year-over-year.
Recorlev Outperformance
Recorlev revenue was $45.3M in Q4 and $139.3M for FY2025, growing more than 100% for both the quarter and full year; patient base ended 2025 at ~700 patients, nearly double year-end 2024.
Durable Contributions from Gvoke and Keveyis
Gvoke generated $24.6M in Q4 and $94.1M for FY2025 (full-year growth of 14%), providing steady, predictable revenue. Keveyis produced $12.8M in Q4 and $47.6M for FY2025 and increased the average number of patients on therapy.
First Full-Year Net Income and Positive Adjusted EBITDA
Company delivered net income for the full year 2025 and adjusted EBITDA of $59.4M for FY2025 (Q4 adjusted EBITDA $25.1M, an improvement of $16.8M year-over-year).
High and Improving Gross Margins
Gross margin was 87% in Q4 and 85% for FY2025, reflecting improvement versus prior year driven by favorable product mix.
Financial Self-Sustainability and Strong Balance Sheet
Management stated the company reached financial self-sustainability in 2025, with an improved balance sheet that provides flexibility to fund growth, advance XP-8121, and support commercial investments.
Ambitious 2026 Guidance
2026 revenue guidance of $375M to $390M (midpoint implying >30% growth versus 2025) with expectation to remain adjusted EBITDA positive and to grow adjusted EBITDA in absolute dollars versus 2025.
Progressing High-Value Pipeline Asset: XP-8121
XP-8121 is on track to initiate Phase III in H2 2026; company projects potential peak sales of $1B–$3B. Management estimates 20M hypothyroid patients on oral therapy with 3M–5M potentially unable to maintain normal ranges due to GI absorption, representing the target opportunity.
Commercial Investment to Drive Future Growth
Recorlev commercial team nearly doubled in January 2026 (sales, patient support, medical affairs, pharmacy services) to accelerate awareness and adoption, with management expecting impact to be notable in H2 2026 and beyond.
Intellectual Property Protection for Recorlev
Company filed a patent infringement lawsuit against two ANDA filers and cites four Orange Book-listed patents for Recorlev that extend to March 2040 plus orphan drug exclusivity through end of 2028.
Negative Updates
Ongoing Recorlev Patent Litigation and Uncertainty
A patent infringement suit was just filed against two ANDA filers; timing and outcome are uncertain (could take months to years), creating potential legal overhang and execution risk despite management's confidence in the patents.
Concentration Risk Centered on Recorlev
Recorlev is the primary growth driver (more than 100% growth and majority of incremental revenue), implying product concentration risk if competitive or regulatory events materially change market dynamics.
Step-Up in R&D Spending to Advance XP-8121
R&D expenses were $31.2M for FY2025 (22% year-over-year increase). Management expects R&D to increase by approximately $25M in 2026 to support Phase III initiation, representing a meaningful near-term investment.
Increased SG&A to Support Commercial Expansion
SG&A was $47.5M in Q4 (+~18% YoY) and $182.4M for FY2025 (+~12% YoY). Management plans to increase SG&A by approximately $45M in 2026 to support Recorlev scaling, which will pressure operating spend before future leverage benefits accrue.
Keveyis and Gvoke Growth Moderation
Keveyis appears to be flattening as a revenue contributor and Gvoke growth is modest (14% full-year), indicating limited near-term upside from these legacy products compared with Recorlev-driven growth.
Seasonal/Short-Term Headwinds in Q1
Management noted typical Q1 payer and copay resets that slowed early 2026 demand, which may cause near-term seasonality and lumpiness in early-quarter performance.
Company Guidance
Xeris guided full‑year 2026 total revenue of $375M–$390M (which represents more than 30% growth at the midpoint versus 2025 total revenue of $291.8M and Q4 revenue of $85.8M), said it will remain adjusted‑EBITDA positive and that adjusted‑EBITDA will grow in absolute dollars versus 2025’s $59.4M, expects a modest improvement in gross margin versus 2025 (FY gross margin 85%, Q4 87%) with gross‑to‑net broadly steady, plans to step up R&D by approximately $25M to support initiation of the XP‑8121 Phase III in H2 2026 (2025 R&D was $31.2M), will increase SG&A by roughly $45M to fund a near‑doubling of the commercial footprint (2025 SG&A was $182.4M), expects partnerships/other revenue to remain in the historical ~5–10% range, and highlighted product metrics (Recorlev ~700 patients and $139.3M FY revenue, >100% growth; Gvoke $94.1M FY, ~14% growth; Keveyis $47.6M FY) along with long‑term peak sales assumptions of $1B for Recorlev by 2035 and $1–3B potential peak sales for XP‑8121.Xeris Pharmaceuticals Financial Statement Overview
Summary
2025 shows a meaningful turnaround with positive EBIT/EBITDA, slightly positive net income, and operating/free cash flow turning positive after prior-year losses and cash burn. The offset is balance-sheet fragility: leverage remains elevated (debt-to-equity ~2.8) and the company recently had negative equity, making durability of the improvement a key risk.Income Statement
Revenue growth has been strong over the last several years (from ~$20M in 2020 to ~$292M in 2025), and profitability inflected meaningfully in 2025 with positive EBIT/EBITDA and slightly positive net income. That said, margins remain thin at the bottom line in 2025 (net margin ~0.2%), and the prior years show sizable losses (2021–2024), indicating the earnings profile is still early and potentially volatile.58
Neutral
Balance Sheet
Leverage improved dramatically in 2025 versus 2024, with total debt dropping sharply and equity turning positive again, which reduces balance-sheet stress. However, leverage is still elevated (debt-to-equity ~2.8 in 2025), and the company has shown periods of negative equity in 2023–2024, highlighting a still-fragile capital structure and higher risk if performance weakens.42
Neutral
Cash Flow
Cash generation improved substantially in 2025, with operating cash flow (~$28.6M) and free cash flow (~$27.9M) turning positive after multiple years of cash burn, and free cash flow growth was strong. A key watch item is that operating cash flow remains modest relative to the scale of revenue and the business recently depended on external funding during loss-making periods, so durability of positive cash flow still needs to be proven.67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M |
| Gross Profit | 238.43M | 166.24M | 135.27M | 87.61M | 36.27M |
| EBITDA | 12.71M | -13.99M | -23.73M | -69.31M | -113.67M |
| Net Income | 554.00K | -54.84M | -62.26M | -94.66M | -122.72M |
Balance Sheet | |||||
| Total Assets | 383.53M | 323.06M | 322.60M | 344.52M | 304.36M |
| Cash, Cash Equivalents and Short-Term Investments | 111.04M | 71.62M | 72.45M | 121.97M | 102.43M |
| Total Debt | 37.76M | 271.45M | 229.19M | 198.06M | 88.07M |
| Total Liabilities | 369.84M | 352.68M | 329.38M | 299.33M | 209.13M |
| Stockholders Equity | 13.69M | -29.61M | -6.78M | 45.19M | 95.23M |
Cash Flow | |||||
| Free Cash Flow | 27.93M | -37.85M | -49.29M | -103.42M | -103.42M |
| Operating Cash Flow | 28.63M | -36.98M | -47.02M | -102.89M | -102.89M |
| Investing Cash Flow | -696.00K | 4.88M | -6.00M | 34.46M | 34.46M |
| Financing Cash Flow | 11.39M | 36.17M | -1.61M | 127.47M | 27.25M |
Xeris Pharmaceuticals Technical Analysis
Negative
6.02
Price Trends
7.15
Negative
7.53
Negative
6.84
Negative
Market Momentum
-0.31
Positive
32.39
Neutral
18.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Negative. The current price of 6.02 is below the 20-day moving average (MA) of 6.70, below the 50-day MA of 7.15, and below the 200-day MA of 6.84, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 32.39 is Neutral, neither overbought nor oversold. The STOCH value of 18.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XERS.
Xeris Pharmaceuticals Risk Analysis
Xeris Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Xeris Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xeris Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.93B | 51.19 | 15.02% | ― | 1128.17% | ― | |
59 Neutral | $1.82B | -24.45 | -26.72% | ― | 116.21% | 43.93% | |
56 Neutral | $1.05B | 2,273.17 | ― | ― | 42.05% | 76.50% | |
56 Neutral | $2.84B | -7.25 | -63.26% | ― | -8.75% | -8.79% | |
56 Neutral | $1.33B | -10.46 | -23.41% | ― | ― | -37.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.89B | -6.38 | -161.82% | ― | 597.19% | 0.45% |
* Healthcare Sector Average
XERS
Xeris Pharmaceuticals
6.07
2.30
61.01%
SNDX
Syndax Pharmaceuticals
21.62
7.14
49.31%
ZYME
Zymeworks
25.23
12.05
91.43%
RCUS
Arcus Biosciences
22.68
12.87
131.19%
STOK
Stoke Therapeutics
34.42
26.26
321.81%
RAPP
Rapport Therapeutics, Inc.
29.34
18.87
180.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.